What is the HIV Ag/Ab (Antigen/Antibody) Combo ECLIA (Electrochemiluminescence Immunoassay) test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

HIV Ag/Ab Combo ECLIA Test

The HIV Ag/Ab Combo ECLIA (Electrochemiluminescence Immunoassay) is a fourth-generation screening test that simultaneously detects both HIV-1/2 antibodies and HIV-1 p24 antigen in blood, allowing for earlier diagnosis of HIV infection compared to antibody-only tests. 1, 2

What This Test Detects

The combination assay identifies two distinct markers of HIV infection:

  • HIV-1 p24 antigen: A viral core protein that appears in blood 14-22 days after infection, before antibodies develop 1
  • HIV-1 and HIV-2 antibodies: Both IgM and IgG antibodies that develop later in the infection course 1

Clinical Advantages

Fourth-generation assays like the ECLIA reduce the diagnostic window period significantly, becoming positive 4-7 days after detectable virus by nucleic acid testing, compared to 7-14 days for third-generation antibody-only tests. 1

The CDC and Association of Public Health Laboratories recommend fourth-generation antigen/antibody combination assays as the initial screening test for HIV diagnosis, with sensitivity and specificity exceeding 99.5%. 2

How Results Are Interpreted

  • Reactive (positive) result: Requires confirmatory testing with an HIV-1/HIV-2 antibody differentiation immunoassay to distinguish between HIV-1 and HIV-2 infections 1
  • If differentiation assay is negative: Nucleic acid amplification testing (NAAT) should be performed to rule out acute HIV-1 infection 1
  • If differentiation assay is positive: Proceed with viral load testing and CD4 count determination to guide management 1

Important Clinical Caveats

The test has a 10-14 day "eclipse period" after infection when no markers are detectable. If initial testing is negative but exposure occurred recently, repeat testing 2-4 weeks later is essential. 1

Antiretroviral drugs can suppress viral load and delay seroconversion, potentially causing false-negative results in persons taking PrEP or PEP. 1 In these situations, both a laboratory-based Ag/Ab test and diagnostic NAAT are recommended for follow-up. 1

In neonates, antibody testing is unreliable due to maternal antibodies; HIV-1 RNA viral load testing should be used instead for diagnosis. 1

Specimen Requirements

The test uses serum or plasma collected in standard tubes (clot tube for serum, EDTA tube for plasma), with optimal transport at room temperature within 2 hours. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

HIV Laboratory Diagnosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.